This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Radius Exceeds 2018 Financial Guidance, Provides Updates
by Zacks Equity Research
Radius (RDUS) exceeds its 2018 financial guidance, with full-year U.S. net sales of its lead drug Tymlos surpassing the upper range of $95-$98 million.
Radius Health (RDUS) Down 6.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Radius Health (RDUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Radius Health (RDUS) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Radius Health, Inc. (RDUS) has been struggling lately, but the selling pressure may be coming to an end soon.
Radius Health (RDUS) Posts Narrower-Than-Expected Q3 Loss
by Zacks Equity Research
Radius Health (RDUS) posts narrower Q3 loss as Tymlos sales gains traction.
Radius Health (RDUS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Radius Health (RDUS) delivered earnings and revenue surprises of 15.84% and 8.52%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Radius Health (RDUS) Q3 Earnings Preview: What to Look Out For
by Zacks Equity Research
Radius Health (RDUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Radius Health (RDUS) Down 11.8% Since Last Earnings Report?
by Zacks Equity Research
Radius Health (RDUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Radius (RDUS) Q2 Loss Narrower Than Expected, Tymlos Sales Up
by Zacks Equity Research
Radius' (RDUS) Q2 results are encouraging as sales of its lead osteoporosis drug, Tymlos, continue to gain traction.
Radius Health (RDUS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Radius Health (RDUS) delivered earnings and revenue surprises of 25.00% and 8.58%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Envision Healthcare (EVHC) Q2 Earnings: What's in Store?
by Zacks Equity Research
Envision Healthcare (EVHC) Q2 earnings should gain from higher revenues from thePhysician Service segment and gains from cost control initiatives.
Is a Beat in Store for Radius Health (RDUS) in Q2 Earnings?
by Zacks Equity Research
Investors will focus on lead drug Tymlos' uptake and an update on Radius Health's (RDUS) marketing application for the drug in Europe, when it reports second-quarter results on Aug 7.
Why Is Radius Health (RDUS) Down 9.7% Since its Last Earnings Report?
by Zacks Equity Research
Radius Health (RDUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Radius Health (RDUS) Incurs Narrower-Than-Expected Q1 Loss
by Zacks Equity Research
Radius Health (RDUS) narrower-than-expected loss in the first quarter was encouraging as sales of lead drug Tymlos pick up amid competition.
What's in Store for Radius Health (RDUS) in Q1 Earnings?
by Zacks Equity Research
Investors are expected to focus on the uptake of lead drug, Tymlos, and other pipeline developments when Radius Health (RDUS) reports results for the first quarter.
Will Cigna (CI) Beat Q1 Earnings Estimates This Time Again?
by Zacks Equity Research
Cigna (CI) Q1 earnings to see upside from higher revenues, enrollment growth.
Radius Health (RDUS) Down 4.3% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Radius Health (RDUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Radius Health Down on Negative CHMP Opinion for Lead Drug
by Zacks Equity Research
Shares of Radius Health (RDUS) declined after the company's application for lead drug, abaloparatide-SC, was given a negative opinion by the CHMP in Europe.
Radius Health Announces Positive Data on Lead Drug Tymlos
by Zacks Equity Research
Radius Health (RDUS) announces positive results from the extended study, ACTIVExtend on its drug Tymlos whcih is approved for the treatment of postmenopausal women with high risk osteoporosis for fracture.
Radius (RDUS) Q4 Loss Wider Than Expected on Higher Expenses
by Zacks Equity Research
Radius Health (RDUS) reported a wider-than-expected loss in the fourth quarter due to higher operating expenses related to the commercialization of Tymlos.
Radius Health (RDUS) to Disappoint Investors in Q4 Earnings?
by Zacks Equity Research
Investors are expected to focus on the uptake of the lead drug, Tymlos when Radius Health (RDUS) reports its fourth-quarter results.
Radius Health to Get Third Day-180 List of Outstanding Issues
by Zacks Equity Research
Radius Health (RDUS) will get a third Day-180 List of Outstanding Issues from the CHMP for its marketing authorisation application of abaloparatide-SC leading to a further delay in tentative approval.
Radius Health (RDUS) Earnings Miss in Q3, Tymlos in Focus
by Zacks Equity Research
Radius Health (RDUS) reported a wider-than-expected loss in third-quarter as expenses grew significantly for the commercialization of Tymlos.
Will Radius Health (RDUS) Disappoint This Earnings Season?
by Zacks Equity Research
Radius Health (RDUS) has a disappointing track record and we expect the trend to continue when it reports third-quarter results on Nov 2.
Radius (RDUS) Enrols First Patient in Breast Cancer Study
by Zacks Equity Research
Radius Health, Inc. (RDUS) announced that the first patient has been enroled in the phase I study on breast cancer candidate RAD140.
Radius Health (RDUS) Down 12.7% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Radius Health (RDUS) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.